UA100865C2 - Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины - Google Patents

Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины

Info

Publication number
UA100865C2
UA100865C2 UAA201006029A UAA201006029A UA100865C2 UA 100865 C2 UA100865 C2 UA 100865C2 UA A201006029 A UAA201006029 A UA A201006029A UA A201006029 A UAA201006029 A UA A201006029A UA 100865 C2 UA100865 C2 UA 100865C2
Authority
UA
Ukraine
Prior art keywords
heading
solid dispersion
dispersion product
normal
aryl urea
Prior art date
Application number
UAA201006029A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Рудольф Шредер
Танья Хайтерманн
Original Assignee
Эбботт Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Гмбх Унд Ко. Кг filed Critical Эбботт Гмбх Унд Ко. Кг
Publication of UA100865C2 publication Critical patent/UA100865C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201006029A 2007-10-19 2008-10-17 Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины UA100865C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99961807P 2007-10-19 2007-10-19
PCT/EP2008/064076 WO2009050291A2 (en) 2007-10-19 2008-10-17 Solid dispersion product of n-aryl urea-based drugs

Publications (1)

Publication Number Publication Date
UA100865C2 true UA100865C2 (ru) 2013-02-11

Family

ID=40089463

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201006029A UA100865C2 (ru) 2007-10-19 2008-10-17 Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины

Country Status (18)

Country Link
EP (1) EP2197425A2 (es)
JP (1) JP2011500649A (es)
KR (1) KR20100087170A (es)
CN (1) CN101827584A (es)
AU (1) AU2008313622A1 (es)
BR (1) BRPI0818340A2 (es)
CA (1) CA2699301A1 (es)
CO (1) CO6270206A2 (es)
CR (1) CR11442A (es)
DO (1) DOP2010000117A (es)
EC (1) ECSP10010183A (es)
GT (1) GT201000102A (es)
MX (1) MX2010004291A (es)
PA (1) PA8800101A1 (es)
RU (1) RU2010119929A (es)
UA (1) UA100865C2 (es)
WO (1) WO2009050291A2 (es)
ZA (1) ZA201002095B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
BR112012031516A2 (pt) * 2010-06-09 2016-11-08 Abbott Lab dispersões sólidas contendo inibidores de quinase
AU2012335663B2 (en) 2011-11-11 2015-12-24 Array Biopharma Inc. Method of treating a proliferative disease
US9387208B2 (en) 2011-11-23 2016-07-12 Novartis Ag Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2014003677A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising solid dispersion particles containing tadalafil

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070104780A1 (en) * 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
AU2007316558A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
GT201000102A (es) 2012-03-12
JP2011500649A (ja) 2011-01-06
ECSP10010183A (es) 2010-06-29
CA2699301A1 (en) 2009-04-23
DOP2010000117A (es) 2010-05-15
AU2008313622A1 (en) 2009-04-23
CR11442A (es) 2010-09-06
ZA201002095B (en) 2011-11-30
PA8800101A1 (es) 2009-05-15
BRPI0818340A2 (pt) 2015-04-22
EP2197425A2 (en) 2010-06-23
CO6270206A2 (es) 2011-04-20
WO2009050291A2 (en) 2009-04-23
WO2009050291A3 (en) 2010-04-08
KR20100087170A (ko) 2010-08-03
RU2010119929A (ru) 2011-11-27
CN101827584A (zh) 2010-09-08
MX2010004291A (es) 2010-08-02

Similar Documents

Publication Publication Date Title
MX2010004292A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea.
UA100865C2 (ru) Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины
TW200640502A (en) Tablets with improved drug substance dispersibility
WO2007123955A3 (en) Stable hydroalcoholic oral spray formulations and methods
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
TW200716202A (en) Pediatric formulation of topiramate
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2010015567A3 (en) Controlled release formulations using intelligent polymers
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
SI2046292T1 (sl) Formulacije za benzimidazolil piridil etre
MX2009010675A (es) Formulaciones farmaceuticas de moleculas de la hormona liberadora de la hormona delcrecimiento humana.
WO2009060952A1 (ja) 新規製剤
NZ602441A (en) A fast dissolving pharmaceutical composition
WO2011076209A3 (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
WO2006110810A3 (en) Polymorphs of 3-o-(3',3'-dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine
WO2006127321A3 (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same
WO2007065625A3 (en) Pharmaceutical compositions of short-acting hypnotic agents in modified-release forms and the procedures to prepare the mentioned formulations
WO2008084864A1 (ja) カプサイシン受容体活性化剤及びそれを噴霧する装置
WO2009008004A3 (en) Sustained release formulations of divalproex sodium
WO2010058104A3 (fr) Compositions pharmaceutiques utilisant l'inuline comme excipient de granulation
WO2008122425A3 (en) Oral compositions containing tacrolimus in amorphous form
WO2009150530A3 (en) Pharmaceutical composition suitable for use as foam comprising 5'-aminosalicylic acid and silicone oil
WO2008105392A1 (ja) 3-アミノ-2-インドリルブチロラクタム誘導体、その製造法、及びこれを有効成分とする医薬
TH104743B (th) ผลิตภัณฑ์แพร่กระจายแข็งที่มีสารประกอบ n-อะริล ยูเรีย
WO2011154830A3 (es) Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa